Skip to main content
ACS Medicinal Chemistry Letters logoLink to ACS Medicinal Chemistry Letters
. 2025 Aug 25;16(9):1703–1708. doi: 10.1021/acsmedchemlett.5c00396

Structural and Molecular Insight into the PWWP1 Domain of NSD2 from the Discovery of Novel Binders Via DNA-Encoded Library Screening

Gavin W Collie †,*, Bryony Ackroyd †, Catriona Corbishley †, Daniel H O’Donovan ‡, Alex Edwards †, Andrea Gohlke †, Xiaoxiao Guo †, Bethan Howells †, Yuliang Li §, Andrew Madin †, Alexander G Milbradt †, Emma L Rivers †,*, Sandeep K Talapatra †, Elizabeth Underwood †, Alice Webb †
PMCID: PMC12434523  PMID: 40959233

Abstract

NSD2 is a key epigenetic regulator and has received considerable attention as a drug target due to its well-documented role in tumorigenesis. We report here a DNA-encoded library screen targeting the PWWP1 domain of NSD2 from which we discovered novel, potent, and selective binders. Furthermore, these compounds were used to develop a novel crystal system, increasing our understanding of the folding of this domain. Together, these results provide a solid molecular and structural basis for the further study of the PWWP1 domain of NSD2 as a cancer drug target.

Keywords: NSD2, DEL, encoded library, drug discovery, PWWP1


graphic file with name ml5c00396_0007.jpg


graphic file with name ml5c00396_0006.jpg


The nuclear receptor-binding SET domain (NSD) family of methyltransferases act as epigenetic regulators, recognizing and catalyzing the methylation of histones. They mainly act on the histone H3 lysine 36 (H3K36). NSD2, also known as MMSET (multiple myeloma SET domain-containing protein) or WHSC1 (Wolf-Hirschhorn syndrome candidate 1), is a member of the NSD protein family and was found to preferentially catalyze dimethylation of H3K36 generating H3K36me2 as the primary product. NSD2 has been recognized as a promising drug target for cancer therapy, with overexpression detected in several human solid tumors, such as prostate, breast, renal and lung cancer, and an oncogenic role in multiple myeloma. Most recently, NSD2 was found to exert oncogenic function in colorectal cancer and an NSD2 E1099K gain of function mutation, leading to a global increase in H3K36me2 levels, was strongly enriched in patients with relapsed acute lymphoblastic leukemia.

Toward the discovery of small molecule inhibitors of NSD2, two domains of this protein have emerged as potential targets. The catalytic SET domain has been the focus of a number of hit finding activities with several inhibitors reported to occupy the catalytic domain and inhibit its methyl transfer function. As the SET domain is highly conserved across the NSD family, selectivity is expected to be a major challenge for inhibitors binding to this site.

An alternative approach which has recently emerged is to target the N-terminal PWWP (PWWP1) domain of NSD2 which binds to nucleosomes containing H3K36me2. The first small molecule antagonist of the PWWP1 domain was identified following virtual screening and subsequently optimized to yield chemical probe UNC6934 (Figure a). This compound showed binding to NSD2-PWWP1 with a K D of 91 nM and cellular activity at 1.23 μM. A second chemotype, developed through structure-based design and based around an imidazole core, was reported as an inhibitor of NSD2-PWWP1 with in vitro potency of 110 nM. The compound demonstrated good selectivity over other PWWP domains and modest cell proliferation inhibitory activity. More recently, PROTACs targeting the NSD2-PWWP1 domain − as well as a series originating from virtual- and knowledge-based methods have also been reported. Despite the number of PWWP1-targetted chemical series there remains scope to develop structurally distinct scaffolds targeting the PWWP1 domain with improved properties and enhanced antiproliferation effects.

1.

1

a) Chemical structure of NSD2-PWWP1 chemical probe UNC6934. b-c) DEL hits identified, representing on-DNA versions of 5 and 11, respectively. d) 3D scatter plot showing enriched features from the pyrimidine-scaffold library against the NSD2 selection condition. Each library member is represented with a unique coordinate, with building blocks from cycle A (BBA) plotted on the z-axis and building blocks from cycle B (BBB) on the x-axis. The y-axis represents a statistical metric of enrichment significance for each disynthon. Point size reflective of the number of DNA sequence counts. e-f) Enrichment profiles of both library members highlighted in the cube view across the three selection conditions (NTC; no target control). Pyridine exemplar shown in b and e and sulfolane exemplar shown in c and f.

Prior to disclosure of the more recent binders, we set out to identify, via DNA-encoded library (DEL) screening, novel potent and selective NSD2-PWWP1 ligands with drug-like properties. DNA-encoded library (DEL) technology is an attractive affinity-based approach to rapidly screen billions of compounds to identify binders to a protein of interest. For the DEL screen selections, we ran both 6xHis-tagged NSD2 (211–350) and NSD3 (263–398) along with a corresponding negative control containing no target, in parallel experiments, to allow us to identify novel and selective binders of NSD2 which showed no interaction with NSD3. The screens were performed using a collection of 1.12 billion compounds which was made up of 27 distinct DNA-encoded chemical libraries.

Data analysis of the selection output was carried out by calculating statistical prevalence data and enrichment profiles for all building block combinations in all of the libraries and across each of the selection conditions. A promising selection of putative hits were identified from a library comprised of two cycles of building block installation around a 2,4-dichloropyrimidine core and containing ∼ 24.8 million different compounds. Enrichment plots and profiles are shown in Figure , where the Enrichment value (negative log10 of the asymptotic significance value, normalized to the naïve library) represents a statistical metric of enrichment significant for each building block pair (also known as a disynthon). From this one library, two clusters of structurally related compounds can be seen which both contain the disubstituted pyrimidine core common to the library scaffold. In one case, significantly enriched features were observed for a series of 7 compounds which all contained the N-(4-pyridylmethyl)­ethanamine building block at cycle A (Figure b). The other series comprised of five compounds with the defining building block being the 3-substituted sulfolane moiety at cycle A (Figure c), with stereochemistry undefined in this building block. The decision to treat these as two distinct clusters was based on the lack of common building blocks shared between them at cycle B, which suggested that they may have divergent SAR and hence should be explored separately (Table S3). Within these clusters the examples with the highest counts and best overall physicochemical properties, highlighted in the cube plot (Figure d), were selected for off-DNA synthesis in order to confirm their binding to NSD2 in a range of biophysical methods. For the design of the off-DNA compounds, 5 and 11, the linker to DNA was truncated back to a methyl group in the 4-position of the pyrimidine core. As noted by looking across the different selection conditions (Figure e and f), both compounds showed no enrichment when screened against NSD3, which was the desired profile we were aiming for.

The synthetic route to both compounds is described in Schemes and . The first scaffold, defined by the 4-pyridine moiety, was prepared starting from commercially available 2,4-dichloro-6-methylpyrimidine (1) (Scheme ). Installation of both amine groups was achieved through sequential nucleophilic aromatic substitution reactions, with only the desired regioisomer separated and taken forward after the first step. Removal of the Boc protecting group then allowed for reaction with isocyanatotrimethylsilane to install the urea functionality.

1. General Synthetic Route to DEL Hit Compound 5 .

1

a Reagents and conditions: (a) DIPEA, DMF, 80 °C, 15 h. (b) Cs2CO3, DMF, 80 °C, 4 h. (c) TFA, DCM, rt, 2 h. (d) (trimethylsilyl)­isocyanate, Et3N, DCM, rt, 3h. (e) chiral separation. No unexpected or unusually high safety hazards were encountered.

2. General Synthetic Route to DEL Hit Compound 11 .

2

a Reagents and conditions: (a) DIPEA, DMF, 80 °C, 16 h. (b) MeI, Cs2CO3, DMF, rt, 2 h. (c) RuPhos Pd G3, Cs2CO3, 1,4-dioxane/H2O, 80 °C, 4 h. (d) Chiral separation. No unexpected or unusually high safety hazards were encountered.

The resulting racemic mixture then underwent chiral separation to isolate both enantiomers. The synthesis of compound 11 commenced with an SNAr reaction at the 4-position of the dichloropyrimidine using primary amine containing the sulfolane moiety (Scheme ). The resulting secondary amine was then capped using iodomethane to install the methyl group. Reaction at the 2-position of the pyrimidine with enantiomerically pure substituted pyrrolidine gave the final compound as a mixture of diastereomers which were separated using preparative chiral chromatography.

In order to confirm the ability of compounds 5 and 11 to bind to the PWWP1 domain of NSD2, we set out to develop an SPR assay. An SPR-compatible protein construct was designed, expressed and purified, encompassing residues 211–350 of human NSD2. These domain boundaries were based on the apo NSD2-PWWP1 crystal structure (PDB entry 5VC8 ) available at the time this work was conducted. In order to validate the protein construct and assay, we used the published tool compound UNC6934, which had been reported to bind to the PWWP1 domain of NSD2 with a K D of 91 nM. However, in our assay we measured a considerably (over 10-fold) weaker K D between this compound and our NSD2-PWWP1 SPR construct of 1.33 μM (Table and Figure S1). Details of the SPR constructs used to assess the UNC6934 compound were then disclosed indicating that slightly wider domain boundaries of 208–368 were used for the researchers’ SPR assay.

1. Biophysical and Biochemical Activity of Compounds 5-7 and 11-13 .

  SPR K D /μM
IC 50 /μM
Compound NSD2 (211–350) NSD2 (208–368) NSD3 (263–398) NSD2 (208–368)
UNC6934 1.33 ± 0.19 0.24 ± 0.03 >30 NT
5 0.92 ± 0.03 0.16 ± 0.03 >30 NT
6 5.83 ± 0.64 0.71 ± 0.09 >30 1.24 ± 0.08
7 0.76 ± 0.01 0.15 ± 0.02 >30 0.21 ± 0.01
11 2.30 ± 0.31 1.02 ± 0.19 No binding NT
12 2.80 ± 0.31 1.47 ± 0.13 No binding 2.49 ± 0.06
13 1.52 ± 0.05 0.75 ± 0.04 No binding 1.31 ± 0.06
a

Biophysical SPR-derived K D values are the mean and standard deviation of at least 3 independent replicates.

b

Biochemical IC50 values are the mean of at least 3 replicates ± SEM, except for 6 and 12, which are the result of two replicates. NT = not tested.

Taking this information into account, we were then able to develop and validate an SPR assay, with a K D measured for UNC6934 of 240 nM, in line with previously reported values. We then measured affinities for compounds 5 and 11 using this assay, with K D values of 160 nM and 1.02 μM determined for 5 and 11, respectively (Table ). NMR reporter assays were also developed for both constructs, confirming both compounds to bind to the H3K36m binding site of NSD2-PWWP1 (Figure S2), with K D values determined to be < 2 μM (i.e., below the limit of quantification of the assays). Pleasingly, both compounds 5 and 11 were determined to have very good solubilities of >1000 μM and 977 μM, respectively (measured at pH 7.4 from dried DMSO stock).

In order to enable structure-guided optimization of these hits we attempted to obtain cocrystal structures of both compounds in complex with the PWWP1 domain of NSD2. Initial attempts to obtain structures using a protein construct based on available published crystal structures (using domain boundaries of 211–350) were not successful. We then designed crystallography constructs in line with the longer SPR construct (encompassing residues 208–368), and fortunately were able to successfully obtain a crystal structure of 11 bound to NSD2-PWWP1 to a resolution of 1.62 Å. The crystal structure shows 11 to bind to the methyl-lysine site of the PWWP1 domain, with the sulfolane group binding deep within the pocket forming bidentate hydrogen bonds to backbone NHs of residues D269 and A270, the central pyrimidine pi-stacking on to the side-chain of Y233 and the terminal amide NH forming a polar contact to the side-chain of E272 (Figure ).

2.

2

Crystal structure of 11 in complex with NSD2-PWWP1. C-terminal residues including β-hairpin motif shown in magenta. Key hydrogen bonds shown as black dashes. PDB accession code 9FOC.

Interestingly, the residues C-terminal to residue G350, which are not present in any of the publicly available NSD2-PWWP1 crystal structures, are well resolved in electron density, and are seen to form a β-hairpin motif which packs closely against the methyl-lysine binding site, in the region of residues D269, A270, P271 (colored magenta in Figure ). Since these residues play a key role in binding compound 11 (and UNC6934), this β-hairpin motif would be expected to stabilize the ligand binding site. Indeed, assessment of 11 (as well as 5) by SPR using the initial shorter construct we investigated (encompassing residues 211–350 of NSD2-PWWP1) revealed lower K D values of 2.3 μM and 0.92 μM for 11 and 5, respectively (see Table ). Together, these data provide a structural rationale for the observed increased binding affinity (as measured by SPR) of 5, 11 and UNC6934 for the PWWP1 construct, encompassing residues 208–368 compared to the shorter construct encompassing residues 211–350, and indicate that residues 208–368 should be the minimal domain boundaries used for further in vitro studies of the PWWP1 domain of NSD2.

Though pleased to have determined a crystal structure of 11 in complex with the PWWP1 domain of NSD2, we were unable to obtain a structure of 5 using this same crystal system. However, noting the exceptionally high solubility of the recombinant protein we were using for crystallization, we decided to replace seven charged surface residues with alanine residues, in an attempt to reduce the overall solubility of the protein (and thereby hopefully encourage crystallogenesis) and also to create new hydrophobic surface patches with the hope of providing new crystal packing opportunities. In total, the following mutations were introduced to the wild-type NSD2-PWWP1 208–368 construct (all >10 Å from the methyl-lysine binding site): K256A, K257A, E285A, E291A, K304A, K312A, and D351A. Rather than attempting further cocrystallization attempts with (racemic) 5, however, we decided to separate and test the individual enantiomers, with the resulting compounds 6 and 7 yielding K D values of 710 nM and 150 nM, respectively. We then took the most active enantiomer (7) into cocrystallization trials using the mutated crystallography construct. Pleasingly, this resulted in a successful structure determination, with a data set refined to 1.96 Å and 7 clearly resolved in electron density. Overall the binding mode of 7 is comparable to that of 11, with the pyridine ring sitting deep in the methyl-lysine binding site, forming a hydrogen bond to the backbone NH of A270, the central pyrimidine ring stacking over Y233, and the penultimate urea NH forming a polar contact to the side-chain of E272 (Figure ).

3.

3

Crystal structure of 7 in complex with NSD2-PWWP1. Key polar contacts are shown as black dashes. PDB accession code 9FOE.

As selectivity over the PWWP1 domain of NSD3 was a key goal of our screening efforts, we developed an SPR assay for NSD3-PWWP1 (see Carlino et al., 2024 for further details). Pleasingly, neither the racemates 5 and 11, nor the equivalent separated enantiomers (6–7 and 12–13) showed any meaningful binding to NSD3-PWWP1 (see Table and Figure S1). We next assessed the activity of the separated enantiomers in a biochemical HTRF assay using a probe known to bind to the H3K36me2 binding site of the PWWP1 domain of NSD2. All compounds tested were shown to be active, with IC50 values in the μM to nM range, with 7 displaying the most potent activity with an IC50 of 210 nM (Table ).

We have described here the discovery of novel and selective binders of the PWWP1 domain of NSD2 by screening a DNA-encoded chemical library encompassing 1.12 billion compounds. These compounds allowed us to validate and develop a novel crystal system for NSD2-PWWP1 which has increased our understanding of the folding of this domain. Overall these results provide a sound chemical and structural basis for further investigations aimed at targeting the NSD2-PWWP1 domain with small molecule ligands.

Supplementary Material

ml5c00396_si_001.pdf (1.9MB, pdf)

Acknowledgments

We thank Dr. Jason Breed for assistance with X-ray data collection and the Soleil and Swiss Light Source synchrotrons for access to facilities. We also thank Dr Peter C. Astles, Dr. Jessie Hao-Ru Hsu, Dr. Luca Carlino, Dr. Jonathan Spencer, and Dr. Philip B. Rawlins for valued scientific input.

Glossary

Abbreviations

DEL

DNA-encoded library

H3K36

histone number 3 lysine number 36

MMSET

multiple myeloma SET domain-containing protein

NSD2

nuclear receptor binding SET domain-containing protein 2

PWWP1

Pro-Trp-Trp-Pro domain 1

SET

Su­(var.)­3–9 enhancer-of-zeste and trithorax

SPR

surface plasmon resonance

HTRF

homogeneous time-resolved fluorescence

WHSC1

Wolf-Hirschhorn syndrome candidate 1

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00396.

  • A document containing details of methods concerning protein production, NMR, SPR, crystallography, biochemical assay, DEL screen and chemistry is available, along with supporting data, figures and tables (PDF)

The manuscript was written through contributions of all authors.

The authors declare no competing financial interest.

References

  1. Husmann D., Gozani O.. Histone lysine methyltransferases in biology and disease. Nat. Struct. Mol. Biol. 2019;26(10):880–889. doi: 10.1038/s41594-019-0298-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Li W., Tian W., Yuan G., Deng P., Sengupta D., Cheng Z., Cao Y., Ren J., Qin Y., Zhou Y., Jia Y., Gozani O., Patel D. J., Wang Z.. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Nature. 2021;590(7846):498–503. doi: 10.1038/s41586-020-03069-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kuo A. J., Cheung P., Chen K., Zee B. M., Kioi M., Lauring J., Xi Y., Park B. H., Shi X., Garcia B. A., Li W., Gozani O.. NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming. Mol. Cell. 2011;44(4):609–620. doi: 10.1016/j.molcel.2011.08.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennett R. L., Swaroop A., Troche C., Licht J. D.. The role of nuclear receptor-binding SET domain family histone lysine methyltransferases in cancer. Cold Spring Harbor Perspect. Med. 2017;7(6):a026708. doi: 10.1101/cshperspect.a026708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen R., Chen Y., Zhao W., Fang C., Zhou W., Yang X., Ji M.. The role of methyltransferase NSD2 as a potential oncogene in human solid tumors. OncoTargets Ther. 2020;13:6837–6846. doi: 10.2147/OTT.S259873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Zhao L.-h., Li Q., Huang Z.-J., Sun M.-X., Lu J.-j, Zhang X.-h, Li G., Wu F.. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer. Cell Death Dis. 2021;12(11):974. doi: 10.1038/s41419-021-04267-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Narang S., Evensen N. A., Saliba J., Pierro J., Loh M. L., Brown P. A., Kolekar P., Mulder H., Shao Y., Easton J., Ma X., Tsirigos A., Carroll W. L.. NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization. Genome Biol. 2023;24(1):64. doi: 10.1186/s13059-023-02905-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Zhang L., Zha X.. Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives. Eur. J. Med. Chem. 2023;250:115232. doi: 10.1016/j.ejmech.2023.115232. [DOI] [PubMed] [Google Scholar]
  9. Sankaran S. M., Wilkinson A. W., Elias J. E., Gozani O.. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin. J. Biol. Chem. 2016;291(16):8465–8474. doi: 10.1074/jbc.M116.720748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ferreira de Freitas R., Liu Y., Szewczyk M. M., Mehta N., Li F., McLeod D., Zepeda-Velázquez C., Dilworth D., Hanley R. P., Gibson E., Brown P. J., Al-Awar R., James L. I., Arrowsmith C. H., Barsyte-Lovejoy D., Min J., Vedadi M., Schapira M., Allali-Hassani A.. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2. J. Med. Chem. 2021;64(3):1584–1592. doi: 10.1021/acs.jmedchem.0c01768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dilworth D., Hanley R. P., Ferreira de Freitas R., Allali-Hassani A., Zhou M., Mehta N., Marunde M. R., Ackloo S., Carvalho Machado R. A., Khalili Yazdi A., Owens D. D. G., Vu V., Nie D. Y., Alqazzaz M., Marcon E., Li F., Chau I., Bolotokova A., Qin S., Lei M., Liu Y., Szewczyk M. M., Dong A., Kazemzadeh S., Abramyan T., Popova I. K., Hall N. W., Meiners M. J., Cheek M. A., Gibson E., Kireev D., Greenblatt J. F., Keogh M.-C., Min J., Brown P. J., Vedadi M., Arrowsmith C. H., Barsyte-Lovejoy D., James L. I., Schapira M.. A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization. Nat. Chem. Biol. 2022;18(1):56–63. doi: 10.1038/s41589-021-00898-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Li N., Yang H., Liu K., Zhou L., Huang Y., Cao D., Li Y., Sun Y., Yu A., Du Z., Yu F., Zhang Y., Wang B., Geng M., Li J., Xiong B., Xu S., Huang X., Liu T.. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors. J. Med. Chem. 2022;65(13):9459–9477. doi: 10.1021/acs.jmedchem.2c00709. [DOI] [PubMed] [Google Scholar]
  13. Hanley R. P., Nie D. Y., Tabor J. R., Li F., Sobh A., Xu C., Barker N. K., Dilworth D., Hajian T., Gibson E., Szewczyk M. M., Brown P. J., Barsyte-Lovejoy D., Herring L. E., Wang G. G., Licht J. D., Vedadi M., Arrowsmith C. H., James L. I.. Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2. J. Am. Chem. Soc. 2023;145(14):8176–8188. doi: 10.1021/jacs.3c01421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. LegaardAndersson J., Christensen J., Kleine-Kohlbrecher D., Vacher Comet I., Fullerton Sto̷ier J., Antoku Y., Poljak V., Moretti L., Dolberg J., Jacso T., Jensby Nielsen S., No̷rregaard-Madsen M., Franch T., Helin K., Cloos P. A. C.. Discovery of NSD2-Degraders from Novel and Selective DEL Hits. Chembiochem. 2023;24(24):e202300515. doi: 10.1002/cbic.202300515. [DOI] [PubMed] [Google Scholar]
  15. Meng F., Xu C., Park K.-S., Kaniskan H. Ü., Wang G. G., Jin J.. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos. J. Med. Chem. 2022;65(15):10611–10625. doi: 10.1021/acs.jmedchem.2c00807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Carlino L., Astles P. C., Ackroyd B., Ahmed A., Chan C., Collie G. W., Dale I. L., O’Donovan D. H., Fawcett C., di Fruscia P., Gohlke A., Guo X., Hao-Ru Hsu J., Kaplan B., Milbradt A. G., Northall S., Petrović D., Rivers E. L., Underwood E., Webb A.. Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches. J. Med. Chem. 2024;67(11):8962–8987. doi: 10.1021/acs.jmedchem.4c00215. [DOI] [PubMed] [Google Scholar]
  17. Peterson A. A., Liu D. R.. Small-molecule discovery through DNA-encoded libraries. Nat. Rev. Drug Discovery. 2023;22(9):699–722. doi: 10.1038/s41573-023-00713-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Faver J. C., Riehle K., Lancia D. R. Jr., Milbank J. B. J., Kollmann C. S., Simmons N., Yu Z., Matzuk M. M.. Quantitative Comparison of Enrichment from DNA-Encoded Chemical Library Selections. ACS Comb. Sci. 2019;21(2):75–82. doi: 10.1021/acscombsci.8b00116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zhang M., Yang Y., Zhou M., Dong A., Yan X., Loppnau P., Min J., Liu Y.. Histone and DNA binding ability studies of the NSD subfamily of PWWP domains. Biochem. Biophys. Res. Commun. 2021;569:199–206. doi: 10.1016/j.bbrc.2021.07.017. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ml5c00396_si_001.pdf (1.9MB, pdf)

Articles from ACS Medicinal Chemistry Letters are provided here courtesy of American Chemical Society

RESOURCES